Previous 10 | Next 10 |
2023-12-21 12:11:22 ET More on Sanofi Sanofi: Expect A Weak 2024 Leading Up To A Strong 2025 R&D Day Sanofi: A Shift In The Story Innate Pharma jumps 15% on licensing natural killer cell engager with Sanofi EU regulators issue positive opinion on ...
2023-12-20 08:00:00 ET Summary Sanofi's Q3 results were lower than expected, causing pressure on its share price. The company reported a decrease in revenue, largely due to FX effects, but saw an increase in underlying revenue at constant exchange rates. Sanofi plans to invest...
2023-12-19 05:30:19 ET Stock futures were little changed on Tuesday after the major averages extended gains in the last session, as Fed officials attempt to rein in bets for earlier and deeper-than-expected rate cuts next year. Here are some of Tuesday's biggest stock movers: B...
2023-12-19 05:14:25 ET More on Innate Pharma, Sanofi Sanofi: A Shift In The Story EU regulators issue positive opinion on Sanofi sleeping sickness drug Biden administration secures 230K more RSV injections for infants For further details see: Innate Pharm...
2023-12-15 12:52:54 ET More on Sanofi R&D Day Sanofi: A Shift In The Story Sanofi Spins Off, Investors Spin Out (Rating Downgrade) Biden administration secures 230K more RSV injections for infants Sanofi pulls the plug on licensing deal with Maze ...
2023-12-14 15:46:45 ET More on AstraZeneca, Sanofi, etc. AstraZeneca: A $1.1B Shot In The Arm From Icosavax Acquisition AstraZeneca Is Feeling The Weight Of The Market In 2023 R&D Day AbbVie, AstraZeneca targeted for improper use of drug patents I...
2023-12-13 11:45:17 ET Summary AstraZeneca is acquiring Icosavax for $1.1 billion, targeting RSV and hMPV, leveraging post-COVID vaccine success. The acquisition complements AstraZeneca’s respiratory focus, including Beyfortus; and signals a shift to a broader vaccine portf...
2023-12-12 08:25:49 ET Summary Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma with plans to begin a Phase 3 clinical trial early ...
2023-12-12 03:49:29 ET Summary Today, we take a deeper look at Denali Therapeutics, a biotech company focused on developing treatments for neurodegenerative and lysosomal storage diseases. Denali's developmental focus has drawn several collaboration partnerships from much larger d...
2023-12-11 16:42:25 ET French drugmaker Sanofi ( NASDAQ: SNY ) on Monday said it would terminate a previously announced licensing deal with U.S. biotech Maze Therapeutics for an investigational Pompe disease treatment candidate, after the agreement was challenged by the U.S. Fe...
News, Short Squeeze, Breakout and More Instantly...
Sanofi ships U.S. influenza vaccines for the 2024/25 season PR Newswire Customers will start receiving shipments from July 10 with additional shipments through October to healthcare provider offices, pharmacies and other immunizers to support fall immunization campaigns. ...
2024-07-09 06:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...